CN115667553A - 致癌chd1l的具有抗结肠直肠癌的临床前活性的小分子抑制剂 - Google Patents

致癌chd1l的具有抗结肠直肠癌的临床前活性的小分子抑制剂 Download PDF

Info

Publication number
CN115667553A
CN115667553A CN202180037594.1A CN202180037594A CN115667553A CN 115667553 A CN115667553 A CN 115667553A CN 202180037594 A CN202180037594 A CN 202180037594A CN 115667553 A CN115667553 A CN 115667553A
Authority
CN
China
Prior art keywords
group
chd1l
inhibitor
groups
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037594.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·V·拉巴贝拉
J·M·阿博特
周琼
A·D·亚伯拉罕
H·埃斯奎尔
B·J·普里加罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Denver
Original Assignee
University of Colorado Denver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Denver filed Critical University of Colorado Denver
Publication of CN115667553A publication Critical patent/CN115667553A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180037594.1A 2020-03-24 2021-03-24 致癌chd1l的具有抗结肠直肠癌的临床前活性的小分子抑制剂 Pending CN115667553A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062994259P 2020-03-24 2020-03-24
US62/994,259 2020-03-24
US202163139394P 2021-01-20 2021-01-20
US63/139,394 2021-01-20
PCT/US2021/023981 WO2021195279A2 (en) 2020-03-24 2021-03-24 Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer

Publications (1)

Publication Number Publication Date
CN115667553A true CN115667553A (zh) 2023-01-31

Family

ID=77892666

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037594.1A Pending CN115667553A (zh) 2020-03-24 2021-03-24 致癌chd1l的具有抗结肠直肠癌的临床前活性的小分子抑制剂

Country Status (6)

Country Link
EP (1) EP4127209A4 (https=)
JP (1) JP2023520330A (https=)
CN (1) CN115667553A (https=)
AU (1) AU2021244209A1 (https=)
CA (1) CA3172987A1 (https=)
WO (1) WO2021195279A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222727A1 (en) * 2021-06-17 2022-12-22 The Regents Of The University Of California E3 ligase inhibitors and methods of use thereof
WO2023055763A2 (en) * 2021-09-30 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectral cancer
CN114457007B (zh) * 2022-02-28 2024-05-28 合肥燃音生物科技有限公司 一种基于微孔板的均一的单类器官模型及其制备方法
CA3250274A1 (en) * 2022-05-02 2023-11-09 Eisbach Bio Gmbh USE OF ALC1 INHIBITORS AND SYNERGY WITH PARPI
CN115290774B (zh) * 2022-07-21 2023-07-21 重庆医科大学 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用
WO2024211314A2 (en) * 2023-04-03 2024-10-10 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of chd1l and uses thereof
WO2025088087A1 (en) 2023-10-25 2025-05-01 Eisbach Bio Gmbh A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers
AU2024366320A1 (en) * 2023-10-25 2026-04-16 Eisbach Bio Gmbh Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs
WO2025093706A1 (en) * 2023-10-31 2025-05-08 Eisbach Bio Gmbh Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan
WO2025129032A1 (en) * 2023-12-15 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Chd1l inhibitors for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211603A1 (en) * 2004-08-18 2006-09-21 Vicuron Pharmaceuticals Inc. Ramoplanin derivatives possessing antibacterial activity
CN102792160A (zh) * 2010-01-08 2012-11-21 新加坡科技研究局 用于治疗癌症的方法和组合物
CN104822380A (zh) * 2012-08-23 2015-08-05 维罗斯塔蒂克斯公司 新颖的4,6-二取代的氨基嘧啶衍生物
CN108976172A (zh) * 2017-05-31 2018-12-11 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
CN109761909A (zh) * 2019-01-25 2019-05-17 中国药科大学 N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140243403A1 (en) * 2011-06-03 2014-08-28 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
US20160138114A1 (en) * 2013-06-19 2016-05-19 The Regents Of The University Of California Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211603A1 (en) * 2004-08-18 2006-09-21 Vicuron Pharmaceuticals Inc. Ramoplanin derivatives possessing antibacterial activity
CN102792160A (zh) * 2010-01-08 2012-11-21 新加坡科技研究局 用于治疗癌症的方法和组合物
CN104822380A (zh) * 2012-08-23 2015-08-05 维罗斯塔蒂克斯公司 新颖的4,6-二取代的氨基嘧啶衍生物
CN108976172A (zh) * 2017-05-31 2018-12-11 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
CN109761909A (zh) * 2019-01-25 2019-05-17 中国药科大学 N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途

Also Published As

Publication number Publication date
JP2023520330A (ja) 2023-05-17
WO2021195279A3 (en) 2021-11-11
WO2021195279A2 (en) 2021-09-30
AU2021244209A1 (en) 2022-11-03
EP4127209A4 (en) 2024-07-24
CA3172987A1 (en) 2021-09-30
EP4127209A2 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
CN115667553A (zh) 致癌chd1l的具有抗结肠直肠癌的临床前活性的小分子抑制剂
Wang et al. Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast cancer with wild-type BRCA
US11452725B2 (en) Chiral diaryl macrocycles and uses thereof
Liu et al. Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors
EP2825160B1 (en) A sik inhibitor for use in a method of treating an inflammatory and/or immune disorder
JP2021020957A (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2022512643A (ja) Ｅ３リガーゼの共有結合による標的化
US9333205B2 (en) Isoxazolo-quinazolines as modulators of protein kinase activity
WO2018133795A1 (zh) 一种ezh2抑制剂及其用途
EA032145B1 (ru) Производные хиноксалина, содержащая их фармацевтическая композиция, их способ получения и применение в профилактике или лечении заболевания или состояния, опосредованного fgfr киназой
AU2016356884A1 (en) Novel compounds as inhibitors of dna methyltransferases
Li et al. Discovery, synthesis, and evaluation of novel dual inhibitors of a vascular endothelial growth factor receptor and poly (Adp-ribose) polymerase for brca wild-type breast cancer therapy
WO2018121400A1 (zh) 酰胺及硫代酰胺类衍生物及其制备方法和应用
WO2022032224A1 (en) Compositions and methods for the treatment and diagnosis of cancer
JP2018513214A (ja) 新規なキナーゼ阻害剤の調製と使用
US20230103444A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
WO2023055763A2 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectral cancer
HK40087586A (zh) 致癌chd1l的具有抗结肠直肠癌的临床前活性的小分子抑制剂
US20250122193A1 (en) Novel pyridocarbazolium compounds and medical uses thereof
WO2024249554A1 (en) Multitarget small molecule inhibitors and uses thereof
Yang et al. Histone Deacetylases-Based Dual Inhibitors: Research Progress Focusing on Non-Small Cell Lung Cancer Therapy
CN114426541A (zh) 氮杂芳基化合物及其用途
CN119013271A (zh) Crk样（CrkL）衔接蛋白抑制剂及其制备和使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087586

Country of ref document: HK

CB03 Change of inventor or designer information

Inventor after: D.V. Rabbabella

Inventor after: J.M. Abbott

Inventor after: Zhou Qiong

Inventor after: H. Esquel

Inventor after: B. J. prigaro

Inventor before: D.V. Rabbabella

Inventor before: J.M. Abbott

Inventor before: Zhou Qiong

Inventor before: A D Abraham

Inventor before: H. Esquel

Inventor before: B. J. prigaro

CB03 Change of inventor or designer information